Advanced search
Publication Cover
Clinical and Experimental Hypertension Volume 38, 2016 - Issue 7
Submit an article Journal homepage
135
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Protection of endothelial cells against Ang II-induced impairment: Involvement of both PPARα and PPARγ via PI3K/Akt pathway

HaiYan ShanDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Siyang ZhangScience Experiment Center, China Medical University, Shenyang, ChinaView further author information
,
Xiaojie WeiDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Xuelian LiDepartment of Epidemiology, College of Public Health China Medical University, Shenyang, ChinaView further author information
,
Huimeng QiDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Yini HeDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Ao LiuDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Donghui LuoDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
&
Xiaosong YuDepartment of General Practice, The First Affiliated Hospital of China Medical University, Shenyang, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 571-577 | Received 16 Nov 2015, Accepted 11 Mar 2016, Published online: 20 Sep 2016

References

  • Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014;16(6):431.
  • Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(23 Suppl 1): III27–32.
  • Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97(8):1916–23.
  • Zafari AM, Ushio-Fukai M, Minieri CA, et al. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal 1999;1(2):167–79.
  • Waghe P, Sarath TS, Gupta P, et al. Arsenic causes aortic dysfunction and systemic hypertension in rats: Augmentation of angiotensin II signaling. Chem Biol Interact 2015;237:104–14.
  • Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292(1), C82–97.
  • Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000;101(3):305–10.
  • Shan H, Zhang S, Li X, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med 2014;18(6):1071–80.
  • Shan H, Guo D, Li X, et al. From autophagy to senescence and apoptosis in Angiotensin II-treated vascular endothelial cells. APMIS 2014;122(10):985–92.
  • Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000;43(4):527–50.
  • Diep QN, Amiri F, Touyz RM, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40(6), 866–71.
  • Kilter H, Werner M, Roggia C, et al. The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes Metab. 2009;11(11):1060–7.
  • Wu JS, Tsai HD, Huang CY, et al. 15-Deoxy-12,14-PGJ 2, by activating peroxisome proliferator-activated receptor-gamma, suppresses p22phox transcription to protect brain endothelial cells against hypoxia-induced apoptosis. Mol Neurobiol 2014;50(1):221–38.
  • Li H, Lu W, Cai WW, et al. Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway. Pulm Pharmacol Ther 2014;28(1):17–24.
  • Ravingerova T, Carnicka S, Nemcekova M, et al. PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: Involvement of PI3K-Akt. Can J Physiol Pharmacol 2012;90(8):1135–44.
  • Imig JD, Walsh KA, Hye Khan MA, et al. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor gamma agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood). 2012;237(12):1402–12.
  • Inoue I, Hayashi K, Yagasaki F, et al. Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor gamma 1 (PPARgamma 1) and PPARalpha genes. J Atheroscler Thromb 2003;10(2):99–108.
  • Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999;274(24):17042–8.
  • Levonen AL, Dickinson DA, Moellering DR, et al. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 2001;21(11):1846–51.
  • Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 2001;90(Suppl 3):125–32.
  • Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002;293(5):1431–7.
  • Kakiuchi-Kiyota S, Arnold LL, Yokohira M, et al. Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology, 2011;287(1–3): 91–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.